Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 20 |
| Active Pipeline (Recruiting Now) | 7 (3) |
| Completed vs Stopped Early | 7 / 4 (20.0%) |
| Median Closed Actual Enrollment | 488 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 2 (2 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Zhejiang Provincial People's Hospital | Hangzhou, Zhejiang | 4 |
| Shenzhen People's Hospital | Shenzhen, Guangdong | 3 |
| Peking University First Hospital | Beijing, Beijing Municipality | 3 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07515079 | Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema | Phase III | RECRUITING |
| NCT06044350 | A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders | Phase II | ACTIVE NOT RECRUITING |
| NCT05141994 | Clinical Study on the Efficacy and Safety of BAT5906 Injection | Phase II | COMPLETED |
| NCT05439629 | Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration | Phase III | COMPLETED |
Explore interactive annual charts and M&A subsidiary rollups in the Bio-Thera Solutions Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.